CybeRelease: (OTC: MNCL) Rated ’Speculative Buy,’ Target Price $0.13 by Beacon Equity Research

(CybeRelease, March 16, 2007) - Lake Harmony, PA - Martin Nutraceuticals, Inc. (OTC PK: MNCL) has been rated “Speculative Buy” with a target price of $0.13 by Beacon Equity Research Analyst, Dr. Victor Sula.

The full report is available at http://www.BeaconEquityResearch.com

Anyone interested in receiving alerts regarding Martin Nutraceuticals, Inc. research should email members@beaconequityresearch.com with “MNCL” in the subject line.

In the report, the analyst writes, "Martin Nutraceuticals is a development-stage company, incorporated in 2004, that develops and markets natural/complimentary medicine for aid in joint and general arthritic pain, digestion issues, blood and circulatory flow, weight control and optimal overall functioning of the human body.

"MNCL products include Arthrizyme(TM) for general joint pain, Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control are designed to improve the activity of the immune system and weight control. MNCL’s family of natural supplements will also include Heartzyme(TM), Digestzyme(TM), Petzyme(TM) and Probiotix(TM).

To read the complete release, go to http://biz.yahoo.com/bw/070316/20070316005733.html?.v=1

For a Free Newsletter, go to http://www.OTCReporter.com

CybeRelease Gainers are Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), Pacific Sunwear of California, Inc. (Nasdaq: PSUN), Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Fieldstone Investment Corporation (Nasdaq: FICC), Informatica Corporation (Nasdaq: INFA), Wet Seal, Inc. (The) (Nasdaq: WTSLA), CEPHEID (Nasdaq: CPHD) and DXP Enterprises, Inc. (Nasdaq: DXPE).

CybeRelease Decliners are Atmel Corporation (Nasdaq: ATML), Adams Respiratory Therapeutics, Inc. (Nasdaq: ARXT), Trimeris, Inc. (Nasdaq: TRMS), OpenTV Corp. (Nasdaq: OPTV), Jupitermedia Corporation (Nasdaq: JUPM), Hythiam, Inc. (Nasdaq: HYTM), Sangamo BioSciences, Inc. (Nasdaq: SGMO) and Allion Healthcare, Inc. (Nasdaq: ALLI).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for informational purposes only and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact Information

C. P. Barry

Media Contact

CybeRelease.com

Contact via E-mail